RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer

An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteShanghai East Hospital, Tongji University同济大学附属东方医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07654400, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Histopathologically and/or cytologically confirmed extensive-stage small cell lung cancer that is incurable or for which there is currently no standard treatment;

    Inclusion criterion 5

  3. Toxicities from prior anti-tumor therapy have recovered to ≤ Grade 1 as defined by NCI-CTCAE v6.0;

    Inclusion criterion 9

    Cumulative anthracycline dose >360 mg/m² during prior (neo)adjuvant anthracycline therapy;

    Exclusion criterion 20

  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;

    Inclusion criterion 8

  5. Must have at least one measurable lesion as defined by RECIST v1.1;

    Inclusion criterion 7

  6. Diagnosis of another malignancy within 5 years before the first dose;

    Exclusion criterion 9

  7. Pregnant or breastfeeding women;

    Exclusion criterion 24

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07654400, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Voluntarily sign the informed consent form and comply with the protocol requirements;
  • No gender restriction;
  • Age: ≥18 years;
  • Expected survival time ≥3 months;
  • Histopathologically and/or cytologically confirmed extensive-stage small cell lung cancer that is incurable or for which there is currently no standard treatment;
  • Agree to provide archived tumor tissue specimens from the primary or metastatic lesion within 3 years, or fresh tissue samples;
  • Must have at least one measurable lesion as defined by RECIST v1.1;
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
  • Toxicities from prior anti-tumor therapy have recovered to ≤ Grade 1 as defined by NCI-CTCAE v6.0;
  • No severe cardiac dysfunction, with left ventricular ejection fraction (LVEF) ≥50%;
  • Organ function levels must meet the required criteria;
  • Urine protein ≤1+ or ≤1000 mg/24h;
  • For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before the start of treatment. Serum pregnancy testing must rule out pregnancy, and the patient must not be breastfeeding. All enrolled trial participants (regardless of gender) should take adequate barrier contraceptive measures throughout the entire treatment period and for 7 months after the end of treatment.

Exclusion Criteria:

  • Use of chemotherapy, biological therapy, immunotherapy, etc., within 4 weeks or 5 half-lives before the first dose;
  • Previous treatment with ADC drugs using topoisomerase I inhibitors as toxins;
  • Small cell carcinoma with non-small cell carcinoma components indicated by pathology must be excluded;
  • Use of immunomodulatory drugs within 2 weeks before the first dose of the study;
  • Receiving long-term systemic corticosteroid therapy at a dose >10 mg/day of prednisone or equivalent before the first dose;
  • History of severe cardiovascular or cerebrovascular diseases;
  • Prolonged QTc interval, complete left bundle branch block, etc.;
  • Active autoimmune diseases and inflammatory diseases;
  • Diagnosis of another malignancy within 5 years before the first dose;
  • Hypertension poorly controlled by two antihypertensive drugs;
  • Patients with poorly controlled blood glucose;
  • History of ILD/interstitial pneumonia treated with corticosteroids, etc.;
  • Concomitant pulmonary diseases leading to clinically severe impairment of respiratory function;
  • Presence of massive serous cavity effusion, or serous cavity effusion with symptoms, etc.;
  • Imaging findings indicating that the tumor has invaded or encased major blood vessels in the chest, neck, pharynx, etc.;
  • Any thrombotic event within 6 months before randomization;
  • Patients with active central nervous system metastases;
  • History of allergy to recombinant humanized antibodies or chimeric human-mouse antibodies, or allergy to any excipient components of the investigational drug, etc.;
  • Previous organ transplantation or allogeneic hematopoietic stem cell transplantation;
  • Cumulative anthracycline dose >360 mg/m² during prior (neo)adjuvant anthracycline therapy;
  • Positive for human immunodeficiency virus antibody, active tuberculosis, active hepatitis B virus infection, or active hepatitis C virus infection;
  • Active infections requiring systemic treatment, or occurrence of severe infection within 4 weeks before informed consent;
  • Receipt of other unapproved clinical study drugs or treatments within 4 weeks before the first dose;
  • Pregnant or breastfeeding women;
  • History of severe neurological or psychiatric disorders;
  • Presence of serious non-healing wounds, ulcers, or fractures within 4 weeks before signing informed consent;
  • Clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing informed consent;
  • History of intestinal obstruction, inflammatory bowel disease, extensive bowel resection, or presence of Crohn's disease, ulcerative colitis, or chronic diarrhea;
  • Trial participants who plan to receive or have received live vaccines within 28 days before the first dose;
  • Other conditions deemed by the investigator to be unsuitable for participation in this clinical trial.

Quoted from ClinicalTrials.gov, NCT07654400, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07654400, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07654400